What should I avoid while taking Aliskiren 300mg tablets?

Do not take with or immediately after a high-fat meal. The absorption of aliskiren is substantially reduced by taking it with high-fat meals. Take with or without food. Take consistently at the same time in regard to meals. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Aliskiren 300mg tablets?

Aliskiren 300mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Aliskiren 300mg tablets?

Aliskiren 300mg tablets is the generic name. It is available under brand names including: Rasilez 300mg tablets, Rasilez 300mg tablets, Rasilez 300mg tablets, Rasilez 300mg tablets, Rasilez 300mg tablets and 2 more. (Source: NHS dm+d — Actual Medicinal Products)

Aliskiren 300mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

300mg

Oral

Antihypertensive

Active ingredients:

Aliskiren

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C09XA02

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antihypertensive

Check interactions for Aliskiren

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Aliskiren

Source: MHRA Products DatabaseOGL 3.0

Updated 16 Jan 2026

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Aliskiren

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Aliskiren

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

7 branded products available

7 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Aliskiren on the MHRA register

Rasilez 300mg tablets

Sigma Pharmaceuticals Plc

Rasilez 300mg tablets

CST Pharma Ltd

Rasilez 300mg tablets

Noden Pharma DAC

Discontinued

Rasilez 300mg tablets

Waymade Healthcare Plc

Discontinued

Rasilez 300mg tablets

Mawdsley-Brooks & Company Ltd

Discontinued

Rasilez 300mg tablets

Lexon (UK) Ltd

Discontinued

Rasilez 300mg tablets

DE Pharmaceuticals

Discontinued

Source: NHS dm+dOGL 3.0

Updated 1 Mar 2026

Daily dose

WHO defined daily dose (DDD)

150 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

1 similar

Aliskiren 150mg tablets

Tablet

150mg

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

39731511000001102

dm+d ID

39731511000001102

VTM (Virtual Therapeutic Moiety)

774471001

VMP (Virtual Medicinal Product)

39731511000001102

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C09XA02

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 16 · Randomised trials: 10 · 2002–2026

Sort

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

Suzanne Oparil, Steven A. Yarows, Samir Patel, et al.

The Lancet, 2007

Randomised trial

Highly cited for its field

Cited by 442

Renin Inhibitors
Valsartan
Amides

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

M. Gheorghiade, M. Böhm, S. Greene, et al.

JAMA, 2013

Randomised trial

Highly cited for its field

Cited by 349

Renin Inhibitors
Amides
Antihypertensive Agents

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis

Ziv Harel, Cameron Gilbert, Ron Wald, et al.

BMJ, 2012

Systematic review

Highly cited for its field

Cited by 119

Amides
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents

Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial

Morris J. Brown, Gordon T. McInnes, Cheraz Cherif Papst, et al.

The Lancet, 2011

Randomised trial

Highly cited for its field

Cited by 165

Amides
Antihypertensive Agents
Calcium Channel Blockers

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

Karl Andersen, Myron H. Weinberger, Brent M. Egan, et al.

Journal of Hypertension, 2008

Randomised trial

Highly cited for its field

Cited by 156

Renin Inhibitors
Amides
Antihypertensive Agents

Potential role of Aliskiren in cancer modulation compared to other Renin-Angiotensin inhibitors: an in-depth review.

De A, Calcutta A, Della Pietra GP, et al.

2025

Systematic review

Cited by 1

Neoplasms
Amides
Fumarates

Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes

N M Mahmudul Alam Bhuiya, Joshua Caballero, Henry N. Young, et al.

The Journal of Clinical Hypertension, 2026

Systematic review

Proteinuria
Hypertension
Amides

Direct Renin Inhibition With Aliskiren Compared to Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Hypertension: A Systematic Review.

Gapizov A, Mohammad A, Singla S, et al.

2025

Systematic review

Comparison of the effectiveness of aliskiren and ramipril for the management of hypertension: A systematic review and meta-analysis.

Alam T, Asif Ansari M

2025

Systematic review

Hypertension
Amides
Fumarates

Aliskiren, ALTITUDE, and the Implications for ATMOSPHERE

John J.V. McMurray, William T. Abraham, Kenneth Dickstein, et al.

European Journal of Heart Failure, 2012

Review

Highly cited for its field

Cited by 1,095

Amides
Antihypertensive Agents
Fumarates

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

37 found

Half-life

30 to 40 hours

Mechanism

Aliskiren is a renin inhibitor.

Food interactions

2 warnings

Human targets

1 target

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

2.5%

Aliskiren is absorbed in the gastrointestinal tract and is poorly absorbed with a bioavailability between 2.0…

Half-life

30 to 40 hours

Plasma half-life for aliskiren can range from 30 to 40 hours [A214172] with an accumulation half-life of about 24 hours.
[A214172]

Protein binding

47-51%

The plasma protein binding of aliskiren ranges from 47-51%.
[A7581][A204305]

Volume of distribution

80%

Unchanged aliskiren accounts for about 80% of the drug found in the plasma.
[A214172][L13994]

Metabolism

80%

About 80% of the drug in plasma following oral administration is unchanged.…

Elimination

0.6%

Aliskiren is mainly excreted via the hepatobiliary route and by oxidative metabolism by hepatic cytochrome enzymes.
[A7581]
…

Clearance

30 mL/min

Aliskiren is partially cleared in the kidneys, and safety data have not been established for patients with a creatinine clearance of less than 30 mL/min.
[L13994]
…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension.[A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.[L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624]

Properties:

solid

Avg. mass: 551.76 Da

View FDA drug label

DrugBank indication

Aliskiren is used for the treatment of hypertension in children above 6 years and adults.
[L13994]
This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.
[L14168][L14171]

Also known as(25)

Aliskiren

Aliskireno

3.4.23.15

Angiotensinogenase

1,4-cineole 2-exo-monooxygenase

1,8-cineole 2-exo-monooxygenase

1.14.14.1

Albendazole monooxygenase (sulfoxide-forming)

Molecular properties(19)

Drug interactions(838)

Known interactions with other medicines. Always consult a healthcare professional.

Duloxetine

Major

DB00476

The risk or severity of orthostatic hypotension and syncope can be increased when Aliskiren is combined with Duloxetine.

Check this interaction

Levodopa

Major

DB01235

The risk or severity of hypotension and orthostatic hypotension can be increased when Aliskiren is combined with Levodopa.

Check this interaction

Risperidone

Moderate

DB00734

Aliskiren may increase the hypotensive activities of Risperidone.

Check this interaction

Cyclosporine

Moderate

DB00091

The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.

Check this interaction

Alfuzosin

Moderate

DB00346

Alfuzosin may increase the hypotensive activities of Aliskiren.

Check this interaction

Olmesartan

Moderate

DB00275

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Olmesartan.

Check this interaction

Losartan

Moderate

DB00678

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Losartan.

Check this interaction

Candesartan cilexetil

Moderate

DB00796

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Candesartan cilexetil.

Check this interaction

Eprosartan

Moderate

DB00876

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Eprosartan.

Check this interaction

Telmisartan

Moderate

DB00966

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Telmisartan.

Check this interaction

Irbesartan

Moderate

DB01029

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Irbesartan.

Check this interaction

Forasartan

Moderate

DB01342

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Forasartan.

Check this interaction

Saprisartan

Moderate

DB01347

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Saprisartan.

Check this interaction

Tasosartan

Moderate

DB01349

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Tasosartan.

Check this interaction

Saralasin

Moderate

DB06763

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Saralasin.

Check this interaction

Fimasartan

Moderate

DB09279

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Fimasartan.

Check this interaction

Candesartan

Moderate

DB13919

The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Candesartan.

Check this interaction

Amifostine

Moderate

DB01143

Aliskiren may increase the hypotensive activities of Amifostine.

Check this interaction

Diazoxide

Moderate

DB01119

Diazoxide may increase the hypotensive activities of Aliskiren.

Check this interaction

Methylphenidate

Moderate

DB00422

Methylphenidate may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Dexmethylphenidate

Moderate

DB06701

Dexmethylphenidate may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Obinutuzumab

Moderate

DB08935

Aliskiren may increase the hypotensive activities of Obinutuzumab.

Check this interaction

Pentoxifylline

Moderate

DB00806

Pentoxifylline may increase the hypotensive activities of Aliskiren.

Check this interaction

Rituximab

Moderate

DB00073

Aliskiren may increase the hypotensive activities of Rituximab.

Check this interaction

Desmopressin

Moderate

DB00035

Desmopressin may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Midodrine

Moderate

DB00211

Midodrine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Isoetharine

Moderate

DB00221

Isoetharine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Atomoxetine

Moderate

DB00289

Atomoxetine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Etomidate

Moderate

DB00292

Etomidate may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Zolmitriptan

Moderate

DB00315

Zolmitriptan may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Protriptyline

Moderate

DB00344

Protriptyline may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Norepinephrine

Moderate

DB00368

Norepinephrine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Phenylephrine

Moderate

DB00388

Phenylephrine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Phenylpropanolamine

Moderate

DB00397

Phenylpropanolamine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Amoxapine

Moderate

DB00543

Amoxapine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Doxapram

Moderate

DB00561

Doxapram may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Atropine

Moderate

DB00572

Atropine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Metaraminol

Moderate

DB00610

Metaraminol may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Sumatriptan

Moderate

DB00669

Sumatriptan may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Nicergoline

Moderate

DB00699

Nicergoline may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Methoxamine

Moderate

DB00723

Methoxamine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Propiomazine

Moderate

DB00777

Propiomazine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Orciprenaline

Moderate

DB00816

Orciprenaline may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Phenmetrazine

Moderate

DB00830

Phenmetrazine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Trifluoperazine

Moderate

DB00831

Trifluoperazine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Dobutamine

Moderate

DB00841

Dobutamine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Pseudoephedrine

Moderate

DB00852

Pseudoephedrine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Ritodrine

Moderate

DB00867

Ritodrine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Terbutaline

Moderate

DB00871

Terbutaline may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Showing 50 of 838 interactions

Food & lifestyle interactions

Advice

Do not take with or immediately after a high-fat meal. The absorption of aliskiren is substantially reduced by taking it with high-fat meals.

Advice

Take with or without food. Take consistently at the same time in regard to meals.

Toxicity & overdose

The oral LD50 of aliskiren in rats is >2000 mg/kg.
[L14294]
Overdose information is limited in the literature, however, an overdose with aliskiren is likely to result in hypotension. Supportive treatment should be initiated in the case of an overdose.
[L13994][L14297]

How it works

Mechanism of action

Aliskiren is a renin inhibitor.[L13994] Renin is secreted by the kidneys when blood volume and renal perfusion decrease. It normally cleaves the protein angiotensinogen to form angiotensin I. Angiotensin I is then converted to angiotensin II, an active protein. Angiotensin II is a potent vasoconstrictor that causes the release of catecholamines into the circulation. It also promotes the secretion of aldosterone in addition to sodium reabsorption, increasing blood pressure. Additionally, angiotensin II acts on the adrenal cortex where it stimulates aldosterone release. Aldosterone increases sodium reabsorption and potassium excretion in the nephron. [L14030]

Aliskiren prevents the above process via binding to renin at its active site, stopping the cleavage of angiotensin, in turn inhibiting the formation of angiotensin I. This ends the cascade of angiotensin II mediated mechanisms that normally increase blood pressure.[A203624]

Pharmacodynamics

Aliskiren reduces blood pressure by inhibiting renin. This leads to a cascade of events that decreases blood pressure, lowering the risk of fatal and nonfatal cardiovascular events including stroke and myocardial infarction.[A7582][L13994]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Aliskiren is absorbed in the gastrointestinal tract and is poorly absorbed with a bioavailability between 2.0 and 2.5%.
[A204305][L13994]
Peak plasma concentrations of aliskiren are achieved between 1 to 3 hours after administration.
[A204305][L13994]
Steady-state concentrations of aliskiren are achieved within 7-8 days of regular administration.
[A7581]

Half-life

Plasma half-life for aliskiren can range from 30 to 40 hours [A214172] with an accumulation half-life of about 24 hours.
[A214172]

Protein binding

The plasma protein binding of aliskiren ranges from 47-51%.
[A7581][A204305]

Volume of distribution

Unchanged aliskiren accounts for about 80% of the drug found in the plasma.
[A214172][L13994]

Metabolism

About 80% of the drug in plasma following oral administration is unchanged. Two major metabolites account for about 1-3% of aliskiren in the plasma. One metabolite is an O-demethylated alcohol derivative and the other is a carboxylic acid derivative.

Minor oxidized and hydrolyzed metabolites may also be found in the plasma.
[A214172][L13994]

Route of elimination

Aliskiren is mainly excreted via the hepatobiliary route and by oxidative metabolism by hepatic cytochrome enzymes.
[A7581]
Approximately one-quarter of the absorbed dose appears in the urine as unchanged parent drug.
[L13994]
One pharmacokinetic study of radiolabeled aliskiren detected 0.6% radioactivity in the urine and more than 80% in the feces, suggesting that aliskiren is mainly eliminated by the fecal route.
[A214172]

Clearance

Aliskiren is partially cleared in the kidneys, and safety data have not been established for patients with a creatinine clearance of less than 30 mL/min.
[L13994]
One pharmacokinetic study revealed an average renal clearance of 1280 +/- 500 mL/hour in healthy volunteers.
[A214181]

Drug targets(1)

Proteins and enzymes this drug interacts with in the body

Renin

BE0000270

REN

inhibitor

Specific functionaspartic-type endopeptidase activity

Cellular location

Secreted

General function & pharmacology

Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney

Metabolizing enzymes(1)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

Transporters(1)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

substrate

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

Scientific references(8)

Vaidyanathan S., Jarugula V., Dieterich H.A., Howard D., Dole W.P.

Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren.

Clinical Pharmacokinetics

200847(8):515-531. doi: 10.2165/00003088-200847080-00002

PMID: 18611061 DOI: 10.2165/00003088-200847080-00002

Gradman A.H., Schmieder R.E., Lins R.L., Nussberger J., Chiang Y., Bedigian M.P.

Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients.

Circulation

2005111(8):1012-1018. doi: 10.1161/01.cir.0000156466.02908.ed

PMID: 15723979 DOI: 10.1161/01.cir.0000156466.02908.ed

Staessen J.A., Li Y., Richart T.

Oral renin inhibitors.

The Lancet

2006368(9545):1449-1456. doi: 10.1016/s0140-6736(06)69442-7

PMID: 17055947 DOI: 10.1016/s0140-6736(06)69442-7

Sanoski C.A.

Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.

Pharmacotherapy

2009 Feb29(2):193-212. doi: 10.1592/phco.29.2.193

PMID: 19170589 DOI: 10.1592/phco.29.2.193

Oh B.H.

Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives.

Expert Opinion on Pharmacotherapy

2007 Nov8(16):2839-49. doi: 10.1517/14656566.8.16.2839

PMID: 17956203 DOI: 10.1517/14656566.8.16.2839

Buczko W., Hermanowicz J.M.

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate.

Clinical Pharmacokinetics

200847(5):285-295. doi: 10.2165/00003088-200847050-00001

PMID: 19066408 DOI: 10.2165/00003088-200847050-00001

Waldmeier F., Glaenzel U., Wirz B., Oberer L., Schmid D., Seiberling M., Valencia J., Riviere G.J., End P., Vaidyanathan S.

Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.

Drug Metabolism and Disposition

2007 Aug35(8):1418-28. doi: 10.1124/dmd.106.013797. Epub 2007 May 17

PMID: 17510248 DOI: 10.1124/dmd.106.013797

Vaidyanathan S., Bigler H., Yeh C., Bizot M.N., Dieterich H.A., Howard D., Dole W.P.

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.

Clinical Pharmacokinetics

200746(8):661-75. doi: 10.2165/00003088-200746080-00003

PMID: 17655373 DOI: 10.2165/00003088-200746080-00003

ATC classification(5 codes)

ATC C09XA54

ATC C09XA53

ATC C09DX02

ATC C09XA02

ATC C09XA52

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Aliskiren hemifumarate(DBSALT001203)

Experimental properties(5)

External resources(1)

Drugs.com

Protein Data Bank entries(1)

2v0z

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Aliskiren

DB09026

CAS number

173334-57-1

UNII (FDA)

502FWN4Q32

InChI Key (molecular fingerprint)

UXOWGYHJODZGMF-QORCZRPOSA-N

Additional database identifiers

Drugs Product Database (DPD)

20175

ChEBI

601027

PubChem Compound

5493444

PubChem Substance

310264980

KEGG Drug

D03208

ChemSpider

4591452

BindingDB

17950

PharmGKB

PA143487910

PDB

C41

Wikipedia

Aliskiren

ChEMBL

CHEMBL1639

ZINC

ZINC000004393164

RxCUI

325646

HUGO Gene Nomenclature Committee (HGNC)

HGNC:9958

GenAtlas

REN

GeneCards

REN

GenBank Gene Database

L00073

GenBank Protein Database

190994

Guide to Pharmacology

2413

UniProtKB

P00797

UniProt Accession

RENI_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite:

DrugBank 6.02024Recommended citation
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
PMID: 37953279
DrugBank 5.02018
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
PMID: 29126136
DrugBank 4.02014
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
PMID: 24203711
DrugBank 3.02011
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
PMID: 21059682
DrugBank 2.02008
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
PMID: 18048412
DrugBank 1.02006
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 8 Mar 2026

Back to medicines

Aliskiren 300mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
3

Chemical identifiers

Aliskiren

Additional database identifiers

DrugBank citations

Aliskiren 300mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science3

Chemical identifiers

Aliskiren

Additional database identifiers

DrugBank citations

Deep science
3